title: The incidence of low eGFR and proteinuria in a large tertiary referral lipid clinic.
abstract: BACKGROUND
  The prevalence of chronic kidney disease (CKD) stages 3 to 5, defined as eGFR <60 ml/min/1.73 m(2) for more than three months, in the United Kingdom (UK) is 8%. We investigated the incidence of low eGFR and proteinuria in patients attending our large tertiary referral lipid clinic in 2008.
  
  
  METHODS
  In 2008, 1,283 patients were seen, of which 1,029 had complete serum lipid and renal profiles. Estimated glomerular filtration rate (eGFR) was calculated for these patients using the 4-variable MDRD formula. The prevalence of low eGFR (eGFR < 60 ml/min/1.73 m(2)) and proteinuria (albumin/creatinine ratio >2.4 mg/mmol or urinary protein excretion >0.06 g/l) was calculated.
  
  
  RESULTS
  The prevalence of low eGFR and proteinuria was 11.2 and 19.4%, respectively. The percentage of patients with serum lipid levels within the target range suggested by international guidelines was lower among those with low eGFR and proteinuria than in the entire study population, despite similar proportions being treated with statins across all groups.
  
  
  CONCLUSIONS
  The prevalences of low eGFR and proteinuria in a group of 1,029 dyslipidaemic patients attending a large tertiary referral lipid clinic were 11.18 and 19.42%, respectively. These levels are much higher than in the general UK population.
authors: Renal and Transplantation Department, Guy's & St Thomas' Hospitals, (King's Health Partners AHSC), 6th Floor, Borough Wing Guy's Hospital, Great Maze Pond, London SE1 9RT, UK. joseph.davies@kcl.ac.uk
authors: Joseph B
authors: JB
authors: Davies
authors: Martin A
authors: MA
authors: Crook
authors: Anthony S
authors: AS
authors: Wierzbicki
authors: David J
authors: DJ
authors: Goldsmith
mesh_terms: D000328:Adult; D000368:Aged; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D050171:Dyslipidemias / Q000150:complications* / Q000188:drug therapy; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D015994:Incidence; D007676:Kidney Failure, Chronic / Q000150:complications / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D010044:Outpatient Clinics, Hospital / Q000706:statistics & numerical data*; D015995:Prevalence; D011507:Proteinuria / Q000150:complications / Q000453:epidemiology*; D006113:United Kingdom / Q000453:epidemiology
chemical_list: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors